CuroNZ News

CuroNZ is pleased to report high level pre-clinical results achieved in patient dog studies in collaboration with Dr Roger Clemmons, Associate professor of Neurology for animals at the University of Florida.  He has applied intra-muscular NRP injections to several patient dogs suffering from spinal cord injury, eye diseases and the dog equivalent of progressive Multiple Sclerosis (degenerative myelopathy). 

We have uploaded a video of ‘Buc’ the dog who has spinal cord injury and the dog equivalent of retinitis pigmentosa, the video shows before and after NRP walking, gait and movement.  Click to view Video. 

Since having NRP injections Buc's eyesight has not deteriorated as would normally be expected in this timeframe and as you can see on the video his gait and walking is much improved.

CuroNZ is a small Biotechnology start-up company with a drug patent portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by one of CuroNZ's Directors, Dr Frank Sieg.

Our plan is to  develop our drug to the end of preclinical and Phase I Clinical development with the aim of licensing it or reaching other commercial arrangements to enable our partners  to take it to market.

Business Overview

• Drug Neural Regeneration Peptides (NRPs)

• Patent claims directed to neural regeneration and protection regarding the central nervous system

• In excess of NZ $3.5 million invested in the development of these compounds to date

• Lead compound in mid to late phase of preclinical development

These exciting peptides have proven efficacy within various animal disease models indicating significant future therapeutic effects for several human central neural system diseases which currently have few treatments and potentially other applications. 

Our drug has huge potential, however, we need additional investment to enable us to achieve our technical and commercial goals.